A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar
A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Use of Insulin Icodec in People Living With Type 1 Diabetes
Novo Nordisk A/S
245 participants
Aug 28, 2025
OBSERVATIONAL
Conditions
Summary
The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 1 diabetes (T1D) will be treated with insulin icodec as prescribed to by their doctor, in accordance with usual clinical practice. This study will last for about 22 to 30 weeks.
Eligibility
Inclusion Criteria7
- Signed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to the protocol).
- The decision to initiate treatment with commercially available insulin icodec has been made by the participant/legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
- Male or female, age greater than or equal to (≥) 18 years at the time of signing informed consent.
- Diagnosed with T1D ≥ 1 year before signing informed consent.
- Treated with multiple daily insulin injections (daily basal insulin analogue and bolus insulin analogue regimen) ≥ 6 months before signing informed consent.
- Available HbA1c value less than or equal to (≤) 90 days prior to the 'Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Initiation visit' (V1) if in line with local clinical practice.
- Treatment naïve to once-weekly insulin prior to the 'Initiation Visit' (V1).
Exclusion Criteria3
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Treatment with any investigational drug within 30 days prior to enrolment into the study.
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Interventions
Participants with T1D will be treated with commercially available insulin icodec.
Locations(35)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07160816